BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

  October 30, 2026

   · 

  5 min read
• Press Releases

  Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

  October 30, 2026

   · 

  1 min read
• Press Releases

  Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

  October 30, 2026

   · 

  7 min read
• Press Releases

  Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026

  October 30, 2026

   · 

  2 min read
• Press Releases

  Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

  October 30, 2026

   · 

  6 min read
• Press Releases

  OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

  October 30, 2026

   · 

  18 min read
• Press Releases

  Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

  October 30, 2026

   · 

  7 min read
• Press Releases

  Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders

  October 30, 2026

   · 

  5 min read
• Press Releases

  Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)

  October 30, 2026

   · 

  3 min read
• Press Releases

  Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  October 30, 2026

   · 

  7 min read